A recent study published by JAMA Surgery intended to pinpoint risk factors for hospital readmission in patients who underwent an emergency general surgery procedure, in hopes of finding out what decreases readmissions in the long run.
Hospital readmission rates following surgery can lead to a decreased quality of patient care and increased medical costs; thus, it has long been a goal in the healthcare field to reduce these rates. A recent study published by JAMA Surgery intended to pinpoint risk factors for hospital readmission in patients who underwent an emergency general surgery (EGS) procedure, in hopes of finding out what decreases readmissions in the long run.
The study investigated patients older than 18 years of age who were undergoing EGS, as found in the California State Inpatient Database on January 15, 2015. Patient demographics, insurance type, Charlson Comorbidity Index score (taking into account co-existing illnesses), length of stay, complications, and discharge disposition were collected as predictors potentially associated with readmission. The strength of each of these associations was then determined using multivariate logistic regression. Hospital readmission within 30 days was recorded.
Out of the 177,511 patients included in the study, 5.91% was readmitted to the hospital within 30 days and 16.8% of those were readmitted at a different hospital than their original. The most common reasons for readmission were surgical site infections, gastrointestinal complications, and pulmonary complications.
From the demographic-based predictors, significantly higher readmission rates were seen in patients older than 65 years, who were black, and who had high Charlson Comorbidity Index scores. Significantly lower readmission rates were seen in patients who stayed in hospital less than 4 days, and in those who were discharged home. Gender had no effect in readmission likelihood.
Independent risk factors for readmission included having a Charlson Comorbidity Index score over 2, being discharged against medical advice, staying in hospital more than 7 days, and having public insurance.
Understanding and identifying these high-risk factors for hospital readmission provides an opportunity to reduce total readmission rates in the future.
“Reducing readmissions is a noble cost-saving goal with benefits not only to the hospitals, but also to the patients,” authors wrote. “However, it is critical to understand the underlying factors associated with readmission to appropriately identify measures that address the true problem.”
The study findings intimate that readmission after EGS procedures is far too common, and that identifying these specific risk factors and targeting patients who exhibit them is the step in the right direction in reducing readmissions. It also contributes further evidence “that we have a great opportunity to intervene on behalf of our patients and improve their outcomes,” said O. Joe Hines, MD, of the David Geffen School of Medicine at University of California, Los Angeles.
Managed Care Reflections: A Q&A With Charles N. (Chip) Kahn III, MPH
July 30th 2025To mark the 30th anniversary of The American Journal of Managed Care (AJMC), each issue in 2025 includes a special feature: reflections from a thought leader on what has changed—and what has not—over the past 3 decades and what’s next for managed care. The August issue features a conversation with Charles N. (Chip) Kahn III, MPH, the president and CEO of the Federation of American Hospitals and a longtime member of the AJMC editorial board.
Read More
FDA Approves Pegcetacoplan for Rare Kidney Diseases C3G, Primary IC-MPGN in Patients 12 and Older
July 29th 2025The FDA approved pegcetacoplan (Empaveli; Apellis Pharmaceuticals) as the first treatment for patients 12 years and older with the rare, severe kidney diseases C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN).
Read More